Objective: To evaluate TDC expression by flow cytometry for surface markers (CD4, CD8 and CD86), transcription factors (Tbet, Foxp3, Gata3 and Rorγt), and cytokines (IFN-γ, TNF-α, IL-10, IL-12 and IL-17) in spleen, liver, lymph node, bone marrow and tumor of 4T1 induced and healthy mice. Results: TDC are more frequent in lymph nodes in the control and tumor groups, compared to the other environments studied (p < 0.0001). When we compare the expression of surface markers between control and 4T1 induced groupswe noted decreased CD4 TDC expression in liver (p = 0.0001), and the same with CD8 TDC expression in spleen (p = 0.0012) and liver (p = 0.0028), as well as the expression of CD86 TDC in spleen and liver (p = 0.0337), in the 4T1-induced tumor group. When comparing transcription factors, there was a decrease TDC Tbet and TDC Foxp3 in spleen and liver (p = 0.0001); and the same with TDC Gata3 in liver (p = 0.0028), and increase in TDC Rorγt in bone marrow in the tumor group (p < 0.0001). Regarding cytokines, we found decreased IFN-γ TDC in spleen (p < 0.0001) and bone marrow (p = 0.0002), and the same with TNF-α TDC in spleen and liver (p < 0.0001), as well as the expression of IL-10 TDC in spleen (p < 0.0001), liver (p < 0.0001) and bone marrow (p < 0,001), of IL-12 TDC in spleen and bone marrow (p < 0,001), and IL-17 TDC in spleen and liver (p < 0,001) in the 4T1-induced tumor group in all comparisons. Phenotypic changes may be driven by the tissue microenvironment in the presence of the tumor. Directions are needed to understand the functionality associated with possible antitumor immunotherapy.